SOPHiA GENETICS SA (SOPH)

Market Cap	328.47M
Revenue (ttm)	62.37M
Net Income (ttm)	-78.98M
Shares Out	65.30M
EPS (ttm)	-1.22
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	27,919
Open	4.81
Previous Close	4.95
Day's Range	4.81 - 5.06
52-Week Range	2.13 - 7.37
Beta	1.18
Analysts	Buy
Price Target	7.75 (+54.08%)
Earnings Date	May 7, 2024

About SOPH

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, Nor...

• Industry: Health Information Services
• Sector: Healthcare
• IPO Date: Jul 23, 2021
• Employees: 430
• Stock Exchange: NASDAQ
• Ticker Symbol: SOPH

Financial Performance

In 2023, SOPH's revenue was $62.37 million, an increase of 31.14% compared to the previous year's $47.56 million. Losses were -$78.98 million, -9.68% less than in 2022.

Analyst Forecast

According to 4 analysts, the average rating for SOPH stock is "Buy." The 12-month stock price forecast is $7.75, which is an increase of 54.08% from the latest price.

Price Target

$7.75

(54.08% upside)

Analyst Consensus: Buy